Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ya Zhao

Showing results (541-550 of 548) with videos related to

Pageof 55
Sort By:
You have reached the last page of results.This site can display upto 548 results.
Journal of Nanobiotechnology|August 9, 2020
Bismuth chelate as a contrast agent for X-ray computed tomographyJi-Jun Fu, Jun-Jie Guo, Ai-Ping Qin, et al.
Frontiers in Neurology|January 3, 2022
Preventing Ischemic Cerebrovascular Events in High-Risk Patients With Non-disabling Ischemic Cerebrovascular Events Using Remote Ischemic Conditioning: A Single-Arm StudyShimeng Liu, Zongen Gao, Ran Meng, et al.
Cancer Medicine|August 24, 2021
Malic enzyme 2 promotes the progression of hepatocellular carcinoma via increasing triglyceride productionShuai Zhang, Zhi-Mei Cheng, Jia-Li Yu, et al.
Science Advances|January 11, 2019
Jasmonate promotes artemisinin biosynthesis by activating the TCP14-ORA complex in <i>Artemisia annua</i>Ya-Nan Ma, Dong-Bei Xu, Ling Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2026
Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II TrialHai-Dong Zhu, Wei-Jun Fan, Chang Zhao, et al.
The Lancet. Digital Health|June 6, 2020
Assessing risk factors for SARS-CoV-2 infection in patients presenting with symptoms in Shanghai, China: a multicentre, observational cohort studyBei Mao, Yang Liu, Yan-Hua Chai, et al.
Science China. Life Sciences|September 6, 2022
The landscape of agingYusheng Cai, Wei Song, Jiaming Li, et al.
Signal Transduction and Targeted Therapy|February 8, 2023
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)Hai-Dong Zhu, Hai-Liang Li, Ming-Sheng Huang, et al.
Pageof 55

Showing results (541-550 of 548) with videos related to

Sort By:
Pageof 55
You have reached the last page of results.This site can display upto 548 results.
Journal of Nanobiotechnology|August 9, 2020
Bismuth chelate as a contrast agent for X-ray computed tomographyJi-Jun Fu, Jun-Jie Guo, Ai-Ping Qin, et al.
Frontiers in Neurology|January 3, 2022
Preventing Ischemic Cerebrovascular Events in High-Risk Patients With Non-disabling Ischemic Cerebrovascular Events Using Remote Ischemic Conditioning: A Single-Arm StudyShimeng Liu, Zongen Gao, Ran Meng, et al.
Cancer Medicine|August 24, 2021
Malic enzyme 2 promotes the progression of hepatocellular carcinoma via increasing triglyceride productionShuai Zhang, Zhi-Mei Cheng, Jia-Li Yu, et al.
Science Advances|January 11, 2019
Jasmonate promotes artemisinin biosynthesis by activating the TCP14-ORA complex in <i>Artemisia annua</i>Ya-Nan Ma, Dong-Bei Xu, Ling Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2026
Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II TrialHai-Dong Zhu, Wei-Jun Fan, Chang Zhao, et al.
The Lancet. Digital Health|June 6, 2020
Assessing risk factors for SARS-CoV-2 infection in patients presenting with symptoms in Shanghai, China: a multicentre, observational cohort studyBei Mao, Yang Liu, Yan-Hua Chai, et al.
Science China. Life Sciences|September 6, 2022
The landscape of agingYusheng Cai, Wei Song, Jiaming Li, et al.
Signal Transduction and Targeted Therapy|February 8, 2023
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)Hai-Dong Zhu, Hai-Liang Li, Ming-Sheng Huang, et al.
Pageof 55